Impact of rivaroxaban on point-of-care assays

Thrombosis Research

Volumn 153, Issue , 2017, Pages 65-70

  Fontana, Pierre ^a   Alberio, Lorenzo ^b   Angelillo Scherrer, Anne ^c   Asmis, Lars M ^d   Korte, Wolfgang ^e   Mendez, Adriana ^f   Schmid, Pirmin ^g   Stricker, Hans ^h   Studt, Jan Dirk ⁱ   Tsakiris, Dimitrios A ^j   Wuillemin, Walter A ^g,k   Nagler, Michael ^c,k  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d Unilabs   (France)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^f CANTONAL HOSPITAL AARAU   (Switzerland)

^g LUZERNER KANTONSSPITAL   (Switzerland)

^h Ospedale La Carita   (Switzerland)

ⁱ UNIVERSITY OF ZURICH   (Switzerland)

^j UNIVERSITY HOSPITAL BASEL   (Switzerland)

^k UNIVERSITY OF BERN   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROTHROMBIN; RIVAROXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD SAMPLING; COAGULOMETER; DRUG BLOOD LEVEL; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; MULTICENTER STUDY; MULTIPLE ELECTRODE AGGREGOMETRY; NORMAL HUMAN; POINT OF CARE TESTING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN RATIO; PROTHROMBIN TIME; THROMBOCYTE FUNCTION ANALYSIS; THROMBOCYTE FUNCTION ANALYZER; THROMBOELASTOGRAPH; THROMBOELASTOGRAPHY; VALIDATION STUDY; ADOLESCENT; BLOOD; BLOOD CLOTTING TEST; CLINICAL TRIAL; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOOD COAGULATION TESTS; FACTOR XA INHIBITORS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PLATELET FUNCTION TESTS; POINT-OF-CARE TESTING; PROSPECTIVE STUDIES; PROTHROMBIN TIME; RIVAROXABAN; THROMBELASTOGRAPHY; YOUNG ADULT;

EID: 85016150017     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2017.03.019     Document Type: Article

References (40)

1. [1] Dargaud, Y., Sorensen, B., Shima, M., Hayward, C., Srivastava, A., Negrier, C., Global haemostasis and point of care testing. Haemophilia 18:Suppl. 4 (2012), 81–88.
2. [2] Nagler, M., Raddatz-Muller, P., Schmid, P., Bachmann, L.M., Wuillemin, W.A., Accuracy of the point-of-care coagulometer CoaguChek XS in the hands of patients. J. Thromb. Haemost. 11:1 (2013), 197–199.
3. [3] Nagler, M., Bachmann, L.M., Schmid, P., Raddatz Muller, P., Wuillemin, W.A., Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: efficacy and safety in a nationwide long-term prospective cohort study. PLoS One, 9(4), 2014, e95761.
4. [4] Shephard, M., Shephard, A., Watkinson, L., Mazzachi, B., Worley, P., Design, implementation and results of the quality control program for the Australian government's point of care testing in general practice trial. Ann. Clin. Biochem. 46:Pt 5 (2009), 413–419.
5. [5] Da Luz, L.T., Nascimento, B., Shankarakutty, A.K., Rizoli, S., Adhikari, N.K., Effect of thromboelastography (TEG(R)) and rotational thromboelastometry (ROTEM(R)) on diagnosis of coagulopathy, transfusion guidance and mortality in trauma: descriptive systematic review. Crit. Care, 18(5), 2014, 518.
6. [6] Ardillon, L., Ternisien, C., Fouassier, M., Sigaud, M., Lefrancois, A., Pacault, M., Ribeyrol, O., Fressinaud, E., Boisseau, P., Trossaert, M., Platelet function analyser (PFA-100) results and von Willebrand factor deficiency: a 16-year ‘real-world’ experience. Haemophilia 21:5 (2015), 646–652.
7. [7] Lassila, R., Platelet function tests in bleeding disorders. Semin. Thromb. Hemost. 42:3 (2016), 185–190.
8. [8] Petricevic, M., Milicic, D., White, A., Boban, M., Mihaljevic, M.Z., Piljic, D., Rotim, A., Buca, A., Mihalj, M., Biocina, B., Development of a concept for a personalized approach in the perioperative antiplatelet therapy administration/discontinuation management based on multiple electrode aggregometry in patients undergoing coronary artery surgery. J. Thromb. Thrombolysis 40:3 (2015), 383–391.
9. [9] Aradi, D., Kirtane, A., Bonello, L., Gurbel, P.A., Tantry, U.S., Huber, K., Freynhofer, M.K., ten Berg, J., Janssen, P., Angiolillo, D.J., Siller-Matula, J.M., Marcucci, R., Patti, G., Mangiacapra, F., Valgimigli, M., Morel, O., Palmerini, T., Price, M.J., Cuisset, T., Kastrati, A., Stone, G.W., Sibbing, D., Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur. Heart J. 36:27 (2015), 1762–1771.
10. [10] Cuker, A., Siegal, D., Monitoring and reversal of direct oral anticoagulants. Hematology Am. Soc. Hematol. Educ. Program 2015 (2015), 117–124.
11. [11] Gibson, C.M., Mehran, R., Bode, C., Halperin, J., Verheugt, F.W., Wildgoose, P., Birmingham, M., Ianus, J., Burton, P., van Eickels, M., Korjian, S., Daaboul, Y., Lip, G.Y., Cohen, M., Husted, S., Peterson, E.D., Fox, K.A., Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N. Engl. J. Med. 375:25 (2016), 2423–2434.
12. [12] Santos-Gallego, C.G., Badimon, L., Badimon, J.J., Direct and specific inhibition of factor Xa: an emerging therapeutic strategy for atherothrombotic disease. Eur. Heart J. Suppl. 16:Supplement A (2014), A56–A60.
13. [13] Adelmann, D., Wiegele, M., Wohlgemuth, R.K., Koch, S., Frantal, S., Quehenberger, P., Scharbert, G., Kozek-Langenecker, S., Schaden, E., Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry. Thromb. Res. 134:4 (2014), 918–923.
14. [14] Casutt, M., Konrad, C., Schuepfer, G., Effect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEM. Anaesthesist 61:11 (2012), 948–953.
15. [15] Eller, T., Busse, J., Dittrich, M., Flieder, T., Alban, S., Knabbe, C., Birschmann, I., Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests. Clin. Chem. Lab. Med. 52:6 (2014), 835–844.
16. [16] Escolar, G., Arellano-Rodrigo, E., Lopez-Vilchez, I., Molina, P., Sanchis, J., Reverter, J.C., Carne, X., Cid, J., Villalta, J., Tassies, D., Galan, A.M., Diaz-Ricart, M., Reversal of rivaroxaban-induced alterations on hemostasis by different coagulation factor concentrates - in vitro studies with steady and circulating human blood. Circ. J. 79:2 (2015), 331–338.
17. [17] Korber, M.K., Langer, E., Ziemer, S., Perzborn, E., Gericke, C., Heymann, C., Measurement and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an in vitro study. Clin. Appl. Thromb. Hemost. 20:7 (2014), 735–740.
18. [18] Dias, J.D., Norem, K., Doorneweerd, D.D., Thurer, R.L., Popovsky, M.A., Omert, L.A., Use of Thromboelastography (TEG) for detection of new oral anticoagulants. Arch. Pathol. Lab. Med. 139:5 (2015), 665–673.
19. [19] Dinkelaar, J., Patiwael, S., Harenberg, J., Leyte, A., Brinkman, H.J., Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate. Clin. Chem. Lab. Med. 52:11 (2014), 1615–1623.
20. [20] Perzborn, E., Heitmeier, S., Laux, V., Buchmuller, A., Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb. Res. 133:4 (2014), 671–681.
21. [21] Arellano-Rodrigo, E., Lopez-Vilchez, I., Galan, A.M., Molina, P., Reverter, J.C., Carne, X., Villalta, J., Tassies, D., Lozano, M., Diaz-Ricart, M., Escolar, G., Coagulation factor concentrates fail to restore alterations in fibrin formation caused by rivaroxaban or Dabigatran in studies with flowing blood from treated healthy volunteers. Transfus. Med. Rev. 29:4 (2015), 242–249.
22. [22] Chojnowski, K., Gorski, T., Robak, M., Trelinski, J., Effects of rivaroxaban therapy on ROTEM coagulation parameters in patients with venous thromboembolism. Adv. Clin. Exp. Med. 24:6 (2015), 995–1000.
23. [23] Mani, H., Herth, N., Kasper, A., Wendt, T., Schuettfort, G., Weil, Y., Pfeilschifter, W., Linnemann, B., Herrmann, E., Lindhoff-Last, E., Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant. Ther. Drug Monit. 36:5 (2014), 624–631.
24. [24] Oswald, E., Velik-Salchner, C., Innerhofer, P., Tauber, H., Auckenthaler, T., Ulmer, H., Streif, W., Results of rotational thromboelastometry, coagulation activation markers and thrombin generation assays in orthopedic patients during thromboprophylaxis with rivaroxaban and enoxaparin: a prospective cohort study. Blood Coagul. Fibrinolysis 26:2 (2015), 136–144.
25. [25] Ebner, M., Peter, A., Spencer, C., Hartig, F., Birschmann, I., Kuhn, J., Wolf, M., Winter, N., Russo, F., Zuern, C.S., Blumenstock, G., Ziemann, U., Poli, S., Point-of-care testing of coagulation in patients treated with non-vitamin K antagonist oral anticoagulants. Stroke 46:10 (2015), 2741–2747.
26. [26] Bowry, R., Fraser, S., Archeval-Lao, J.M., Parker, S.A., Cai, C., Rahbar, M.H., Grotta, J.C., Thrombelastography detects the anticoagulant effect of rivaroxaban in patients with stroke. Stroke 45:3 (2014), 880–883.
27. [27] Schoergenhofer, C., Schwameis, M., Brunner, M., Zeitlinger, M., Winkler, F., Jilma, B., Brunner-Ziegler, S., Assessing the influence of diurnal variations and selective Xa inhibition on whole blood aggregometry. Scand. J. Clin. Lab. Invest. 75:6 (2015), 531–536.
28. [28] Olivier, C.B., Weik, P., Meyer, M., Weber, S., Anto-Michel, N., Diehl, P., Zhou, Q., Geisen, U., Bode, C., Moser, M., TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran. Thromb. Res. 138 (2016), 63–68.
29. [29] Olivier, C.B., Weik, P., Meyer, M., Weber, S., Diehl, P., Bode, C., Moser, M., Zhou, Q., Dabigatran and rivaroxaban do not affect AA- and ADP-induced platelet aggregation in patients receiving concomitant platelet inhibitors. J. Thromb. Thrombolysis, 2016.
30. [30] Zemer-Wassercug, N., Haim, M., Leshem-Lev, D., Orvin, K.L., Vaduganathan, M., Gutstein, A., Kadmon, E., Mager, A., Kornowski, R., Lev, E.I., The effect of dabigatran and rivaroxaban on platelet reactivity and inflammatory markers. J. Thromb. Thrombolysis 40:3 (2015), 340–346.
31. [31] CLSI, Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays and Molecular Hemostasis Assays; Approved Guideline. fifth ed., 2008, Clinical and Laboratory Standards Institute, Wayne, PA (CLSI document H21-A5).
32. [32] Nagler, M., ten Cate, H., Kathriner, S., Casutt, M., Bachmann, L.M., Wuillemin, W.A., Consistency of thromboelastometry analysis under scrutiny: results of a systematic evaluation within and between analysers. Thromb. Haemost. 111:6 (2014), 1161–1166.
33. [33] Christensen, T.D., Larsen, T.B., Precision and accuracy of point-of-care testing coagulometers used for self-testing and self-management of oral anticoagulation therapy. J. Thromb. Haemost. 10:2 (2012), 251–260.
34. [34] Favaloro, E.J., Clinical utility of the PFA-100. Semin. Thromb. Hemost. 34:8 (2008), 709–733.
35. [35] Peerschke, E.I., Castellone, D.D., Stroobants, A.K., Francis, J., Reference range determination for whole-blood platelet aggregation using the multiplate analyzer. Am. J. Clin. Pathol. 142:5 (2014), 647–656.
36. [36] Rohde, G., Determination of rivaroxaban—a novel, oral, direct factor Xa inhibitor—in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 872:1–2 (2008), 43–50.
37. [37] Favaloro, E.J., Lippi, G., Laboratory testing in the era of direct or non-vitamin K antagonist oral anticoagulants: a practical guide to measuring their activity and avoiding diagnostic errors. Semin. Thromb. Hemost. 41:2 (2015), 208–227.
38. [38] Nagler, M., Wuillemin, W., Laboratory diagnostic with regard to new anticoagulants - monitoring and influence on coagulation tests. Ther. Umsch. 69:11 (2012), 650–656.
39. [39] Herrmann, R., Thom, J., Wood, A., Phillips, M., Muhammad, S., Baker, R., Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb. Haemost. 111:5 (2014), 989–995.
40. [40] Lang, T., Bauters, A., Braun, S.L., Potzsch, B., von Pape, K.W., Kolde, H.J., Lakner, M., Multi-centre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul. Fibrinolysis 16:4 (2005), 301–310.